Aniket A Kawatkar1, Albert J Farias2,3, Chun Chao2, Wansu Chen2, Richard Barron4, Florian D Vogl4, David B Chandler4. 1. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA. Aniket.A.Kawatkar@kp.org. 2. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA. 3. Department of Health Services, University of Washington, Seattle, WA, USA. 4. Amgen Inc., Thousand Oaks, CA, USA.
Abstract
PURPOSE: The study objective was to evaluate chemotherapy treatment patterns and incidence, cost, and resource utilization of febrile neutropenia-related hospitalization (FNH) in patients with breast cancer, lung cancer, and non-Hodgkin's lymphoma (NHL) from Kaiser Permanente Southern California (KPSC), a large integrated delivery system. METHODS: Adults ≥18 years with any stage breast cancer, lung cancer, or NHL who initiated myelosuppressive chemotherapy from 01/01/2006 to 12/31/2009 were included. Chemotherapy dose delays ≥7 days, relative dose intensity (RDI), regimen switching, FNH and all-cause mortality, granulocyte colony-stimulating factor (G-CSF) and antibiotic use, and healthcare utilization/cost were evaluated by cancer type, regimen, and/or cycle. RESULTS: Among 3314 breast cancer patients, 25.3% received an RDI ≤85%, 13.9% experienced FNH with an all-cause mortality rate of 2.0%, and 20.2% received primary prophylaxis with G-CSF. Among those with FNH, mean hospital length of stay (LOS) was 4.1 days, and mean total costs were $20,462. Among 1443 lung cancer patients, 17.9% had an RDI ≤85%, 8.0% experienced FNH with an all-cause mortality rate of 25.2%, and 4.5% received primary prophylaxis with G-CSF. Among those with FNH, mean LOS was 6.8 days, and mean total costs were $32,964. Among 581 NHL patients, 27.9% had an RDI ≤85% and 22.4% experienced FNH with an all-cause mortality rate of 13%. Among those with FNH, mean LOS was 7.9 days, and mean total costs were $37,555. CONCLUSIONS: Marked variability was observed among different cancer types and chemotherapy regimens. Given the variability, detailed insight into incidence, management, and burden of FN can help inform clinical decision making.
PURPOSE: The study objective was to evaluate chemotherapy treatment patterns and incidence, cost, and resource utilization of febrile neutropenia-related hospitalization (FNH) in patients with breast cancer, lung cancer, and non-Hodgkin's lymphoma (NHL) from Kaiser Permanente Southern California (KPSC), a large integrated delivery system. METHODS: Adults ≥18 years with any stage breast cancer, lung cancer, or NHL who initiated myelosuppressive chemotherapy from 01/01/2006 to 12/31/2009 were included. Chemotherapy dose delays ≥7 days, relative dose intensity (RDI), regimen switching, FNH and all-cause mortality, granulocyte colony-stimulating factor (G-CSF) and antibiotic use, and healthcare utilization/cost were evaluated by cancer type, regimen, and/or cycle. RESULTS: Among 3314 breast cancerpatients, 25.3% received an RDI ≤85%, 13.9% experienced FNH with an all-cause mortality rate of 2.0%, and 20.2% received primary prophylaxis with G-CSF. Among those with FNH, mean hospital length of stay (LOS) was 4.1 days, and mean total costs were $20,462. Among 1443 lung cancerpatients, 17.9% had an RDI ≤85%, 8.0% experienced FNH with an all-cause mortality rate of 25.2%, and 4.5% received primary prophylaxis with G-CSF. Among those with FNH, mean LOS was 6.8 days, and mean total costs were $32,964. Among 581 NHLpatients, 27.9% had an RDI ≤85% and 22.4% experienced FNH with an all-cause mortality rate of 13%. Among those with FNH, mean LOS was 7.9 days, and mean total costs were $37,555. CONCLUSIONS: Marked variability was observed among different cancer types and chemotherapy regimens. Given the variability, detailed insight into incidence, management, and burden of FN can help inform clinical decision making.
Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544
Authors: Otavio A C Clark; Gary H Lyman; Aldemar A Castro; Luciana G O Clark; Benjamin Djulbegovic Journal: J Clin Oncol Date: 2005-06-20 Impact factor: 44.544
Authors: T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana Journal: J Clin Oncol Date: 1989-11 Impact factor: 44.544
Authors: Shannon L Michels; Rich L Barron; Matthew W Reynolds; Karen Smoyer Tomic; Jingbo Yu; Gary H Lyman Journal: Pharmacoeconomics Date: 2012-09-01 Impact factor: 4.981
Authors: Seo Young Kim; Daniel H Solomon; Jun Liu; Chun-Lan Chang; Gregory W Daniel; Sebastian Schneeweiss Journal: Pharmacoepidemiol Drug Saf Date: 2011-05-12 Impact factor: 2.890
Authors: G H Lyman; D C Dale; E Culakova; M S Poniewierski; D A Wolff; N M Kuderer; M Huang; J Crawford Journal: Ann Oncol Date: 2013-06-20 Impact factor: 32.976
Authors: Derek Weycker; Oleg Sofrygin; Kim Seefeld; Robert G Deeter; Jason Legg; John Edelsberg Journal: BMC Health Serv Res Date: 2013-02-13 Impact factor: 2.655
Authors: Camille C Gunderson; Britt K Erickson; Ivy Wilkinson-Ryan; Sara K Vesely; Charles A Leath; Paola A Gehrig; Kathleen N Moore Journal: Am J Clin Oncol Date: 2019-02 Impact factor: 2.339
Authors: Robert S Epstein; Upal K Basu Roy; Matti Aapro; Tehseen Salimi; Donald Moran; JoAnn Krenitsky; Megan L Leone-Perkins; Cynthia Girman; Courtney Schlusser; Jeffrey Crawford Journal: Patient Prefer Adherence Date: 2021-02-25 Impact factor: 2.711
Authors: Karen A Monuszko; Benjamin Albright; Mary Katherine Montes De Oca; Nguyen Thao Thi Nguyen; Laura J Havrilesky; Brittany A Davidson Journal: Gynecol Oncol Rep Date: 2021-08-27
Authors: Reshma L Mahtani; Rajesh Belani; Jeffrey Crawford; David Dale; Lucy DeCosta; Prasad L Gawade; Chanh Huynh; Tatiana Lawrence; Sandra Lewis; William W MacLaughlin; Mohit Narang; Robert Rifkin Journal: Support Care Cancer Date: 2022-04-14 Impact factor: 3.603